The main purpose of predicting lifetime height in children with precocious puberty is to better guide clinical management. First of all, before treatment, if the base height is significantly higher than that of children of the same age at the beginning of development, the growth rate of height and the growth rate of bone age are still balanced, or the momentum of sexual maturation is not strong, that is, the process of sexual maturation is slow, and the level of ovarian secretion of estrogen is relatively low, the adult height of these children may not be impaired, and the height prediction by bone age can suggest that their adult lifetime height is basically normal, so it is not necessary to consider treatment with gonadotropin-releasing hormone analogs (GnRha). GnRha analogs may not be considered for treatment. Instead, treatment with GnRha is required. If there is an increase in height with the course of treatment, it indicates that the treatment is effective and should be continued; if the initial predicted growth in height is no longer increased or the growth is not obvious, there may be two reasons, one is that the treatment dose is high and the dose of GnRha should be reduced on a trial basis, and the other is that GnRha inhibits the gonads while the growth axis is also involved. The second is that GnRha is also involved in the growth axis while suppressing the gonads, so a combination of growth hormone therapy can be tried. Finally, if the skeletal radiographs suggest that healing is near, there is little potential for further growth, and there is little difference between the predicted height and the current height, it is time to stop treatment.